PTPRO

Across TCGA pan-cancer cohorts, PTPRO Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PTPRO data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PTPRO Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTPRO expression acts as an unfavorable survival marker, although some lineages such as SKCM and LUSC show a favorable association.

STAD, LUAD, and BLCA are the cancer types where PTPRO Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.208	0.574	.004	15	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	15	view →
BLCA	OS	Median	IV	0.178	0.603	.003	6	view →
SKCM	OS	Median	III,IV	1.000	0.689	.036	4	view →
SCLC	OS	Median	All	0.236	0.586	.032	3	view →
LUSC	DFS	Median	All	0.918	0.736	.043	3	view →
UCEC	DFS	Median	All	0.896	0.622	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PTPRO–STAD (OS)

Open the STAD breakdown →